Clinical Trial Update: A Study Comparing The Bioequivalence Of Ciclesonide Nasal Spray (Apotex, Inc.) To That Of Omnaris™ Nasal Spray (Sepracor, Inc.) In The Treatment Of Seasonal Allergic Rhinitis [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing the bioequivalence of Apotex's ciclesonide nasal spray to Omnaris nasal spray in seasonal allergic rhinitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Seasonal Allergic Rhinitis

Drugs mentioned

• Apotex Ciclesonide Nasal Spray (ciclesonide)
• Omnaris Nasal Spray (ciclesonide)

Snippet

Sponsor: Apotex Inc. | Conditions: Seasonal Allergic Rhinitis | Phase 3 | Status: COMPLETED